Detail akcie Tandem Diabetes Rg online

Business Summary: Tandem Diabetes Care, Inc. is a global insulin delivery and diabetes technology company, which manufactures and sells advanced automated insulin delivery systems. Its pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Its t:slim X2 and Tandem Mobi pumps can be used with a variety of infusion sets to offer patients choice in how and where their pump is worn. In addition, they are software updatable from a personal computer and compatible with its Web-based data management application. Both pumps feature its Control-IQ advanced hybrid closed loop technology, with an automated insulin delivery (AID) feature designed to help increase a user's time in targeted glycemic range. There are two primary therapies used by people with insulin-dependent diabetes, Multiple Daily Injection (MDI) and insulin pumps. As part of it AID systems, it offers pump integration with multiple CGM sensors.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Tandem Diabetes Care Inc revenues decreased 7% to $747.7M. Net loss increased from $94.6M to $222.6M. Revenues reflect Pump segment decrease of 13% to $374.3M. Higher net loss reflects Acquired in-process research and develop increase from $31M to $78.8M (expense), Research and development - Balancing val increase of 21% to $144.1M (expense).